logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

Melanoma: adjuvant dabrafenib, trametinib combination confers durable response

5-year relapse-free survival was superior in phase 3 COMBI-AD trial.